Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Ghiam Yamin is active.

Publication


Featured researches published by Ghiam Yamin.


Proceedings of the National Academy of Sciences of the United States of America | 2007

Familial Alzheimer's disease mutations alter the stability of the amyloid β-protein monomer folding nucleus

Marianne A. Grant; Noel D. Lazo; Aleksey Lomakin; Margaret M. Condron; Hiromi Arai; Ghiam Yamin; Alan C. Rigby; David B. Teplow

Amyloid β-protein (Aβ) oligomers may be the proximate neurotoxins in Alzheimers disease (AD). Recently, to elucidate the oligomerization pathway, we studied Aβ monomer folding and identified a decapeptide segment of Aβ, 21Ala–22Glu–23Asp–24Val–25Gly–26Ser–27Asn–28Lys–29Gly–30Ala, within which turn formation appears to nucleate monomer folding. The turn is stabilized by hydrophobic interactions between Val-24 and Lys-28 and by long-range electrostatic interactions between Lys-28 and either Glu-22 or Asp-23. We hypothesized that turn destabilization might explain the effects of amino acid substitutions at Glu-22 and Asp-23 that cause familial forms of AD and cerebral amyloid angiopathy. To test this hypothesis, limited proteolysis, mass spectrometry, and solution-state NMR spectroscopy were used here to determine and compare the structure and stability of the Aβ(21–30) turn within wild-type Aβ and seven clinically relevant homologues. In addition, we determined the relative differences in folding free energies (ΔΔGf) among the mutant peptides. We observed that all of the disease-associated amino acid substitutions at Glu-22 or Asp-23 destabilized the turn and that the magnitude of the destabilization correlated with oligomerization propensity. The Ala21Gly (Flemish) substitution, outside the turn proper (Glu-22–Lys-28), displayed a stability similar to that of the wild-type peptide. The implications of these findings for understanding Aβ monomer folding and disease causation are discussed.


Journal of Neuroscience Research | 2009

NMDA receptor–dependent signaling pathways that underlie amyloid β-protein disruption of LTP in the hippocampus

Ghiam Yamin

Alzheimers disease (AD), the most common neurodegenerative disease in the elderly population, is characterized by the hippocampal deposition of fibrils formed by amyloid β‐protein (Aβ), a 40‐ to 42‐amino‐acid peptide. The folding of Aβ into neurotoxic oligomeric, protofibrillar, and fibrillar assemblies is believed to mediate the key pathologic event in AD. The hippocampus is especially susceptible in AD and early degenerative symptoms include significant deficits in the performance of hippocampal‐dependent cognitive abilities such as spatial learning and memory. Transgenic mouse models of AD that express C‐terminal segments or mutant variants of amyloid precursor protein, the protein from which Aβ is derived, exhibit age‐dependent spatial memory impairment and attenuated long‐term potentiation (LTP) in the hippocampal CA1 and dentate gyrus (DG) regions. Recent experimental evidence suggests that Aβ disturbs N‐methyl‐D‐aspartic acid (NMDA) receptor–dependent LTP induction in the CA1 and DG both in vivo and in vitro. Furthermore, these studies suggest that Aβ specifically interferes with several major signaling pathways downstream of the NMDA receptor, including the Ca2+‐dependent protein phosphatase calcineurin, Ca2+/calmodulin‐dependent protein kinase II (CaMKII), protein phosphatase 1, and cAMP response element–binding protein (CREB). The influence of Aβ on each of these downstream effectors of the NMDA receptor is reviewed in this article. Additionally, other mechanisms of LTP modulation, such as Aβ attenuation of α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid (AMPA) receptor currents, are briefly discussed.


Biochemistry | 2009

A peptide hairpin inhibitor of amyloid β-protein oligomerization and fibrillogenesis

Ghiam Yamin; Piotr Ruchala; David B. Teplow

Amyloid beta-protein (Abeta) self-assembly is linked strongly to Alzheimers disease. We found that PP-Leu, a tridecapeptide analogue of broad-spectrum antiviral peptides termed theta-defensins, potently inhibits Abeta oligomer and fibril formation. This effect appeared to be mediated through sequestration of the amyloidogenic Abeta peptide in colloid-like assemblies. PP-Leu comprises a turn formed by a d-Pro-l-Pro amino acid dyad and stabilized by a disulfide bond, a motif that was exceptionally resistant to endoproteinase K digestion. This combination of assembly inhibitory activity and protease resistance suggests that PP-Leu may have potential therapeutic value.


Journal of Neurochemistry | 2015

Inhibiting amyloid β-protein assembly: Size-activity relationships among grape seed-derived polyphenols.

Eric Y. Hayden; Ghiam Yamin; Shiela Beroukhim; Benson Chen; Mikhail Kibalchenko; Lin Jiang; Lap Ho; Jun Wang; Giulio Maria Pasinetti; David B. Teplow

Epidemiological evidence that red wine consumption negatively correlates with risk of Alzheimers disease has led to experimental studies demonstrating that grape seed extracts inhibit the aggregation and oligomerization of Aβ in vitro and ameliorate neuropathology and behavioral deficits in a mouse model of Alzheimers disease. The active agent in the extracts is a mixed population of polyphenolic compounds. To evaluate the relative potency of each of these compounds, HPLC was used to fractionate the mixture into monomers, dimers, and oligomers. Each fraction was analyzed for its effect on Aβ conformational dynamics (circular dichroism), oligomerization (zero‐length photochemical cross‐linking), aggregation kinetics (Thioflavin T fluorescence), and morphology (electron microscopy). The relative activities of each fraction were determined on the basis of molar concentration (mol/L) or mass concentration (g/L). When molar concentration, the number concentration of each polyphenolic compound, was considered, the oligomer fraction was the most potent inhibitor of Aβ oligomerization and aggregation. However, when mass concentration, the number concentration of phenolic groups, was considered, monomers were the most potent inhibitors. To understand these ostensibly contradictory results, a model of polyphenol:Aβ complexation was developed. This model, which was found to be consistent with published X‐ray crystallographic studies, offers an explanation for the effects of functional group polyvalency on inhibitor activity. Our data emphasize the importance of an in‐depth understanding of the mechanism(s) underlying ‘concentration dependence’ in inhibitor systems involving polyfunctional agents.


Biochemistry | 2015

Design and Characterization of Chemically Stabilized Aβ42 Oligomers.

Ghiam Yamin; Tien-Phat Vuong Huynh; David B. Teplow

A popular working hypothesis of Alzheimers disease causation is amyloid β-protein oligomers are the key neuropathogenetic agents. Rigorously elucidating the role of oligomers requires the production of stable oligomers of each size. We previously used zero-length photochemical cross-linking to allow stabilization, isolation, and determination of structure-activity relationships of pure populations of Aβ40 dimers, trimers, and tetramers. We also attempted to study Aβ42 but found that Aβ42 oligomers subjected to the same procedures were not completely stable. On the basis of the fact that Tyr is a critical residue in cross-linking chemistry, we reasoned that the chemical accessibility of Tyr10 in Aβ42 must differ from that in Aβ40. We thus chemically synthesized four singly substituted Tyr variants that placed the Tyr in different positions across the Aβ42 sequence. We then studied the stability of the resulting cross-linked oligomers as well as procedures for fractionating the oligomers to obtain pure populations of different sizes. We found that [Phe(10),Tyr(42)]Aβ42 produced stable oligomers yielding highly pure populations of dimers through heptamers. This provides the means to establish formal structure-activity relationships of these important Aβ42 assemblies. In addition, we were able to analyze the dissociation patterns of non-cross-linked oligomers to produce a model for oligomer formation. This work is relevant to the determination of structure-activity relationships that have the potential to provide mechanistic insights into disease pathogenesis.


Journal of Neurochemistry | 2017

Pittsburgh Compound‐B (PiB) binds amyloid β‐protein protofibrils

Ghiam Yamin; David B. Teplow

The neuropathology of Alzheimers disease (AD) includes amyloid plaque formation by the amyloid β‐protein (Aβ) and intracellular paired helical filament formation by tau protein. These neuropathogenetic features correlate with disease progression and have been revealed in brains of AD patients using positron emission tomography (PET). One of the most useful positron emission tomography imaging agents has been Pittsburgh Compound‐B (PiB). However, since its introduction in 2002, substantial evidence has accumulated suggesting that Aβ oligomerization and protofibril formation, rather than fibril formation per se, may be the more important pathogenetic event in AD. Detecting protofibrils and oligomeric forms of Aβ thus may be of value. We report here the results of experiments to determine whether PiB binds to oligomers or protofibrils formed by Aβ40 and Aβ42. We observed strong binding to Aβ42 fibrils, significant binding to protofibrils, and weaker binding to Aβ42 oligomers. PiB also binds Aβ40 fibrils, but its binding to Aβ40 protofibrils and oligomers is substantially lower than for that observed for Aβ42.


Biochemistry | 2004

Role of individual methionines in the fibrillation of methionine-oxidized α-synuclein

Mark Hokenson; Vladimir N. Uversky; John Goers; Ghiam Yamin; Larissa A. Munishkina; Anthony L. Fink


Current Pharmaceutical Design | 2008

Amyloid β -Protein Assembly as a Therapeutic Target of Alzheimers Disease

Ghiam Yamin; Kenjiro Ono; Mohammed Inayathullah; David B. Teplow


Biochemistry | 2005

Forcing nonamyloidogenic β-synuclein to fibrillate

Ghiam Yamin; Larissa A. Munishkina; Mikhail A. Karymov; Yuri L. Lyubchenko; Vladimir N. Uversky; Anthony L. Fink


Biochemistry | 2016

Design, Characterization, and Use of a Novel Amyloid β-Protein Control for Assembly, Neurotoxicity, and Gene Expression Studies

Ghiam Yamin; Giovanni Coppola; David B. Teplow

Collaboration


Dive into the Ghiam Yamin's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Mikhail A. Karymov

University of Nebraska Medical Center

View shared research outputs
Top Co-Authors

Avatar

Vladimir N. Uversky

Laboratory of Molecular Biology

View shared research outputs
Top Co-Authors

Avatar

Yuri L. Lyubchenko

University of Nebraska Medical Center

View shared research outputs
Top Co-Authors

Avatar

John Goers

California Polytechnic State University

View shared research outputs
Top Co-Authors

Avatar

Vladimir N. Uversky

Laboratory of Molecular Biology

View shared research outputs
Top Co-Authors

Avatar

Alan C. Rigby

Beth Israel Deaconess Medical Center

View shared research outputs
Top Co-Authors

Avatar

Aleksey Lomakin

Massachusetts Institute of Technology

View shared research outputs
Researchain Logo
Decentralizing Knowledge